Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes

2007160 citationsJournal Article

Authors

M Hanefeld · GWT-TUD (Germany)

Gary Herman · Merck & Co., Inc., Rahway, NJ, USA (United States)

Mei Wu · Merck & Co., Inc., Rahway, NJ, USA (United States)

Carolyn Mickel · Merck & Co., Inc., Rahway, NJ, USA (United States)

Matilde Sanchez · Merck & Co., Inc., Rahway, NJ, USA (United States)

Peter P. Stein · Merck & Co., Inc., Rahway, NJ, USA (United States)

on behalf of the Sitagliptin Study 014 investigators

Abstract

Sitagliptin monotherapy improved indices of glycemic control compared to placebo and was generally well-tolerated in patients with type 2 diabetes. The glycemic response to treatment with sitagliptin 100 mg/day was similar between the sitagliptin 100-mg once-daily and 50-mg twice-daily dose regimens.

Topics & Keywords

Diabetes Treatment and Management Peptidase Inhibition and Analysis Pancreatic function and diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Current Medical Research and Opinion

Volume 23, Issue 6, pp. 1329-1339

DOI: 10.1185/030079907x188152

Field-Weighted Citation Impact: 10.07